Cambridge id 5781441

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: Cambridge id 5781441
• 英文别名: 6-nitro-N-[1-(2-phenylethyl)piperidin-4-yl]-2,3,4,9-tetrahydro-1H-carbazol-1-amine
• 化学式: C25H30N4O2
• 分子量: 418.5
• InChiKey: INQLGBNCSRSMMK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  76.9
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] NOVEL MEANS AND METHODS FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM, METABOLIC AND CARDIAC DISEASES AND AGING<br/>[FR] NOUVEAUX MOYENS ET MÉTHODES POUR LE TRAITEMENT DE MALADIES DU SYSTÈME NERVEUX CENTRAL, DE MALADIES CARDIAQUES ET MÉTABOLIQUES ET DU VIEILLISSEMENT
  申请人：UNIV MUENCHEN L MAXIMILIANS

  公开号：WO2013139929A1

  公开（公告）日：2013-09-26

  This invention relates to a compound of formula (la) or (Ila) wherein either (A) R1 is I and R2 is selected from substituted or unsubstituted piperidinyl, preferably N-substituted or unsubstituted piperidin-4-yl; substituted or unsubstituted cyclohexyl, cyclopentyl, or cyclohexyl alkyl; substituted or unsubstituted aryl-alkyl; alkyl; aryl; - CHO; and hydrogen; or (B) R1 is selected from halogen; substituted or unsubstituted alkoxy; substituted or unsubstituted alkyl; cyano; and hydrogen; and R2 is substituted or unsubstituted piperidinyl, preferably N-substituted or unsubstituted piperidin-4-yl; and R3, R4 and R5 independently are either H or defined as R1; R6 is H; alkyl or aryl-alkyl, or R2 and R6 together with the N attached thereto form a 5- or 6-membered ring, preferably pyrrol; each of the m occurrences of R7 is independently selected from C1 to C4 alkyl, C1 to C4 alkoxy and halogen, preferably F; and m being 0, 1, 2, 3 or 4; X is selected from NH; N-alkyl, preferably NCH3; N- aryl-alkyl; S; and O; wherein in formula (la) R2 and X together may alternatively form or comprise a 6-membered ring, said 6-membered ring preferably being piperazine; n is 0, 1 or 2; the substituents being independently selected from alkyl, aryl-alkyl; alkoxy, aryl, hydroxy; halogen; oxo; and thio; alkyl being branched, unbranched and/or cyclic C1 to C10 alkyl, preferably branched or unbranched C1 to C4 alkyl, more preferably methyl, ethyl, n-propyl, i- propyl, i-butyl or t-butyl; alkoxy being C1 to C4 alkoxy, preferably methoxy; aryl being phenyl, naphthyl or tetrahydronaphthyl, preferably phenyl; or a compound of any one of Tables 3 to 46; or a salt or hydrate thereof.

  本发明涉及一种化合物，其化学式为（Ia）或（IIa），其中（A）R1为I，R2选自取代或未取代的哌啶基，优选N-取代或未取代的哌啶-4-基；取代或未取代的环己基、环戊基或环己基烷基；取代或未取代的芳基-烷基；烷基；芳基；-CHO；和氢；或者（B）R1选自卤素；取代或未取代的烷氧基；取代或未取代的烷基；氰基；和氢；R2为取代或未取代的哌啶基，优选N-取代或未取代的哌啶-4-基；R3、R4和R5独立地为H或被定义为R1；R6为H；烷基或芳基-烷基，或者R2和R6与其连接的N共同形成5-或6-成员环，优选吡咯；每个R7的m次出现独立地选自C1到C4烷基、C1到C4烷氧基和卤素，优选F；m为0、1、2、3或4；X选自NH；N-烷基，优选NCH3；N-芳基-烷基；S；和O；其中在化学式（Ia）中，R2和X共同可以形成或包含一个6-成员环，该6-成员环优选为哌嗪；n为0、1或2；取代基独立地选自烷基、芳基-烷基；烷氧基、芳基、羟基；卤素；氧化物；和硫代基；烷基为支链、直链和/或环状C1到C10烷基，优选支链或直链C1到C4烷基，更优选甲基、乙基、正丙基、异丙基、异丁基或叔丁基；烷氧基为C1到C4烷氧基，优选甲氧基；芳基为苯基、萘基或四氢萘基，优选苯基；或者为表3至表46中的任一化合物；或其盐或水合物。
• Compounds for The Reduction of The Deleterious Activity of Extended Nucleotide Repeat Containing Genes
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US20200147069A1

  公开（公告）日：2020-05-14

  Aspects of the present disclosure include methods of reducing the deleterious impact of a target gene in a cell, such as the deleterious activity of a mutant extended nucleotide repeat (NR) containing target gene in a cell by contacting the cell with an effective amount of a tetrahydrocarbazolamine compound. The deleterious activity (e.g., toxicity and/or dis-functionality of products encoded thereby) of a mutant extended NR containing target gene may be reduced, e.g., by reducing (and in some instances differentially, including selectively, reducing) the production or activity of toxic expression products (e.g., RNA or protein) encoded by the target gene. Kits and compositions for practicing the subject methods are also provided.